Bing Liu

Dr. Bing Liu

1. The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China
+1

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
SLSu‐Ran Li
Su‐Ran Li
QMQi‐Wen Man
Qi‐Wen Man
XGXin Gao
Xin Gao
HLHao Lin
Hao Lin
JWJing Wang
Jing Wang
GCGang Chen
Gang Chen
Extracellular vesicles (EVs) are lipid‐bilayer membrane structures secreted by most cell types. EVs act as messengers via the horizontal transfer of lipids, proteins, and nucleic acids, and influence various pathophysiological processes in both parent and recipient cells. Compared to EVs obtained from body fluids or cell culture supernatants, EVs isolated directly from tissues possess a number of advantages, including tissue specificity, accurate reflection of tissue microenvironment, etc., thus, attention should be paid to tissue‐derived EVs (Ti‐EVs). Ti‐EVs are present in the interstitium of tissues and play pivotal roles in intercellular communication. Moreover, Ti‐EVs provide an excellent snapshot of interactions among various cell types with a common histological background. Thus, Ti‐EVs may be used to gain insights into the development and progression of diseases. To date, extensive investigations have focused on the role of body fluid‐derived EVs or cell culture‐derived EVs; however, the number of studies on Ti‐EVs remains insufficient. Herein, we summarize the latest advances in Ti‐EVs for cancers and non‐cancer diseases. We propose the future application of Ti‐EVs in basic research and clinical practice. Workflows for Ti‐EV isolation and characterization between cancers and non‐cancer diseases are reviewed and compared. Moreover, we discuss current issues associated with Ti‐EVs and provide potential directions.

23 March 2022 in Medcomm
Verified
Journal Article
Open access
HWHan‐Qi Wang
Han‐Qi Wang
QMQi‐Wen Man
Qi‐Wen Man
FHFang‐Yi Huo
Fang‐Yi Huo
XGXin Gao
Xin Gao
HLHao Lin
Hao Lin
Lin-Lin BuLin-Lin Bu
Lin-Lin Bu
Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in biological functions. The duration of STAT3 activation in normal tissues is a transient event and is strictly regulated. However, in cancer tissues, STAT3 is activated in an aberrant manner and is induced by certain cytokines. The continuous activation of STAT3 regulates the expression of downstream proteins associated with the formation, progression, and metastasis of cancers. Thus, elucidating the mechanisms of STAT3 regulation and designing inhibitors targeting the STAT3 pathway are considered promising strategies for cancer treatment. This review aims to introduce the history, research advances, and prospects concerning the STAT3 pathway in cancer. We review the mechanisms of STAT3 pathway regulation and the consequent cancer hallmarks associated with tumor biology that are induced by the STAT3 pathway. Moreover, we summarize the emerging development of inhibitors that target the STAT3 pathway and novel drug delivery systems for delivering these inhibitors. The barriers against targeting the STAT3 pathway, the focus of future research on promising targets in the STAT3 pathway, and our perspective on the overall utility of STAT3 pathway inhibitors in cancer treatment are also discussed.

18 July 2023 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
NZNian-Nian Zhong
Nian-Nian Zhong
HWHan-Qi Wang
Han-Qi Wang
XHXin-Yue Huang
Xin-Yue Huang
ZLZi-Zhan Li
Zi-Zhan Li
LCLei-Ming Cao
Lei-Ming Cao
Lin-Lin BuLin-Lin Bu
Lin-Lin Bu
1

11 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
YCYang Mm Chen
Yang Mm Chen
NZNian-Nian Mm Zhong
Nian-Nian Mm Zhong
LCLei-Ming Mm Cao
Lei-Ming Mm Cao
Bing LiuBing Liu
Bing Liu
Lin-Lin BuLin-Lin Bu
Lin-Lin Bu
Head and neck squamous cell carcinoma (HNSCC), a prevalent and frequently recurring malignancy, often necessitates surgical intervention. The surgical margin (SM) plays a pivotal role in determining the postoperative treatment strategy and prognostic evaluation of HNSCC. Nonetheless, the process of clinical appraisal and assessment of the SMs remains a complex and indeterminate endeavor, thereby leading to potential difficulties for surgeons in defining the extent of resection. In this regard, we undertake a comprehensive review of the suggested surgical distance in varying circumstances, diverse methods of margin evaluation, and the delicate balance that must be maintained between tissue resection and preservation in head and neck surgical procedures. This review is intended to provide surgeons with pragmatic guidance in selecting the most suitable resection techniques, and in improving patients’ quality of life by achieving optimal functional and aesthetic restoration. Export

14 June 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SLSu-Ran Li
Su-Ran Li
FHFang-Yi Huo
Fang-Yi Huo
HWHan-Qi Wang
Han-Qi Wang
JWJing Wang
Jing Wang
Chun XuChun Xu
Chun Xu
Lin-Lin BuLin-Lin Bu
Lin-Lin Bu
Cancer immunotherapy is a novel therapeutic regimen because of the specificity and durability of immune modulations to treat cancers. Current cancer immunotherapy is limited by some barriers such as poor response rate, low tumor specificity and systemic toxicities. Porous nanomaterials (PNMs) possess high loading capacity and tunable porosity, receiving intense attention in cancer immunotherapy. Recently, novel PNMs based drug delivery systems have been employed in antitumor immunotherapy to enhance tissue or organ targeting and reduce immune-related adverse events. Herein, we summarize the recent progress of PNMs including inorganic, organic, and organic–inorganic hybrid ones for cancer immunotherapy. The design of PNMs and their performance in cancer immunotherapy are discussed in detail, with a focus on how those designs can address the challenges in current conventional immunotherapy. Lastly, we present future directions of PNMs for cancer immunotherapy including the challenges and research gaps, providing new insights about the design of PNMs for efficient cancer immunotherapy with better performance as powerful weapons against tumors. Finally, we discussed the relevant challenges that urgently need to be addressed in clinical practice, coupled with corresponding solutions to these problems.

21 November 2021 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
Lin-Lin BuLin-Lin Bu
Lin-Lin Bu
HWHan-Qi Wang
Han-Qi Wang
YPYuanwei Pan
Yuanwei Pan
LCLei Chen
Lei Chen
HWHao Wu
Hao Wu
ZSZhi-Jun Sun
Zhi-Jun Sun
Matrix metalloproteinase (MMP) 2 and 9 are the family members of proteases normally up-regulated in tumor to enhance the invasion and metastatic of tumor cells, and are associated with poor outcome of head and neck squamous cell carcinomas (HNSCCs). In the present work, MMPs-degradable gelatin nanoparticles (GNPs) are simultaneously loaded with photosensitizer indocyanine green (ICG) along with signal transducer activator of transcription 3 (STAT3) inhibitor NSC74859 (NSC, N) for efficient photothermal therapy (PTT) and immunotherapy of HNSCCs. In the tumor tissue, Gel-N-ICG nanoparticle was degraded and encapsulated ICG and NSC were effectively released. Under near-infrared (NIR) irradiation, the released ICG nanoparticles enabled effective photothermal destruction of tumors, and the STAT3 inhibitor NSC elicited potent antitumor immunity for enhanced cancer therapy. Based on two HNSCC mouse models, we demonstrated that Gel-N-ICG significantly delayed tumor growth without any appreciable body weight loss. Taken together, the strategy reported here may contribute that the stimuli-responsive proteases triggered nanoplatform could reduce tumor size more effectively in complex tumor microenvironment (TME) through combination of PTT and immunotherapy. Graphical Abstract